GeoVax Announces Completion of GEO-MVA Fill-Finish, Supporting Phase 3 Immunobridging Clinical Trial Start-Up in Early 2026

Stock Information for GeoVax Labs Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About GeoVax Labs Inc.

Presenting on Emerging Growth Conference 86 Day 2 September 25; Register to live stream
Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream
Presenting on Emerging Growth Conference 84 Day 1 on July 16; Register to live stream
Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.